{
  "trial_id": "NCT01522469",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, liver function (total or direct bilirubin, ALT, AST), renal function (serum creatinine), prior treatment with FLT3 TKIs, prior allogeneic stem cell transplant, presence of FLT3-ITD or other FLT3 activating mutations, percentage of blasts in blood or marrow at screening, history of HIV or hepatitis B/C infection, ability to swallow pills, major surgical procedures within 14 days of treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "FLT3 status",
          "presence of FLT3-ITD or other FLT3 activating mutations"
        ],
        [
          "Baseline ECOG Performance",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Number of prior therapies"
      ],
      "remaining_candidate_features": [
        "liver function (total or direct bilirubin, ALT, AST)",
        "renal function (serum creatinine)",
        "prior treatment with FLT3 TKIs",
        "prior allogeneic stem cell transplant",
        "percentage of blasts in blood or marrow at screening",
        "history of HIV or hepatitis B/C infection",
        "ability to swallow pills",
        "major surgical procedures within 14 days of treatment"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Liver Function (Bilirubin, ALT, AST), Renal Function (Serum Creatinine), FLT3 Mutation Status, Prior Anti-leukemic Therapy, Post-transplant Status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "FLT3 status",
          "FLT3 Mutation Status"
        ],
        [
          "Baseline ECOG Performance",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Number of prior therapies"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Liver Function (Bilirubin, ALT, AST)",
        "Renal Function (Serum Creatinine)",
        "Prior Anti-leukemic Therapy",
        "Post-transplant Status"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, FLT3-ITD and/or other FLT3 activating mutations, Prior treatment with FLT3 TKIs, Prior allogeneic stem cell transplant, Baseline white blood cell count, Baseline absolute blast count, Baseline bone marrow blast percentage, Baseline peripheral blood blast percentage.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "FLT3 status",
          "FLT3-ITD and/or other FLT3 activating mutations"
        ],
        [
          "Baseline ECOG Performance",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Number of prior therapies"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Prior treatment with FLT3 TKIs",
        "Prior allogeneic stem cell transplant",
        "Baseline white blood cell count",
        "Baseline absolute blast count",
        "Baseline bone marrow blast percentage",
        "Baseline peripheral blood blast percentage"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, FLT3 mutation type (ITD and/or other activating mutations), prior treatment with FLT3 TKIs, prior allogeneic stem cell transplant, time from initial diagnosis to relapse, number of prior relapses, baseline white blood cell count, baseline blast percentage in blood and marrow, liver function tests (total bilirubin, direct bilirubin, ALT, AST), renal function (serum creatinine), presence of liver involvement with leukemia.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "FLT3 status",
          "FLT3 mutation type (ITD and/or other activating mutations)"
        ],
        [
          "Baseline ECOG Performance",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Number of prior therapies"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "prior treatment with FLT3 TKIs",
        "prior allogeneic stem cell transplant",
        "time from initial diagnosis to relapse",
        "number of prior relapses",
        "baseline white blood cell count",
        "baseline blast percentage in blood and marrow",
        "liver function tests (total bilirubin, direct bilirubin, ALT, AST)",
        "renal function (serum creatinine)",
        "presence of liver involvement with leukemia"
      ]
    }
  }
}